A CaseWise™ Webcast: From Research to Real-World: ADCs, IO Combinations, and Sequencing in Metastatic NSCLC

Antibody-drug conjugates (ADCs) are redefining precision oncology by delivering potent therapies directly to tumor cells through highly specific molecular targeting. This innovative approach is rapidly becoming a cornerstone of cancer care, particularly in metastatic non-small cell lung cancer (mNSCLC). Despite their growing impact, the mechanisms behind ADCs remain unclear for many clinicians and multidisciplinary care teams. At the same time, the expanding use of immuno-oncology (IO) therapies in mNSCLC has introduced overlapping toxicity profiles that can obscure the identification and management of ADC-related adverse events. To confidently navigate this evolving landscape, clinicians need best-in-class education that demystifies ADC mechanisms, translates clinical trial and biomarker data into actionable patient selection strategies, and differentiates safety profiles to optimize care for patients with mNSCLC.

In this Creative Educational Concepts recorded webcast, expert faculty will delineate class-wide and agent-specific characteristics of ADCs, including mechanism of action, relevant biomarkers, efficacy, toxicity profiles, and considerations for sequencing and integration of IO therapies in biomarker-selected mNSCLC. Faculty will model evidence-based interpretation of emerging clinical trial data for TROP2-directed and other ADCs to clarify their potential role across diverse mNSCLC patient populations. By strengthening clinicians’ confidence in evidence interpretation and toxicity management, this program supports more informed and individualized treatment selection for patients with mNSCLC.

At the conclusion of this activity, learners will be able to better:

• Differentiate the class-wide and agent-specific characteristics of ADCs, including mechanisms, biomarkers, efficacy, toxicity, and considerations for sequencing and IO integration, in biomarker-selected mNSCLC
• Interpret emerging clinical evidence and biomarker data for TROP2-directed ADCs to determine their potential role across diverse mNSCLC patient populations
• Evaluate the toxicity profiles and monitoring considerations of ADCs and immune checkpoint inhibitors in metastatic NSCLC to support accurate recognition and timely management of treatment-related and overlapping adverse events

This educational activity is supported by an independent educational grant from Gilead Sciences, Inc.

Academic and community medical oncologists, pathologists, molecular pathologists, thoracic surgeons, nurses, nurse practitioners (NPs), physician associates (PAs), pharmacists, and other members of the lung cancer care team

It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CE Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Faculty:

Dr. Garassino reports the following financial relationships:

Advisory Board: Abbvie Inc.; AstraZeneca; Bayer; Bristol Myers Squibb Company; BioNTech SE; Daiichi Sankyo, Inc.; Gilead Sciences, Inc.; IO Biotech; Janssen Pharmaceuticals, Inc; Lilly; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Natera, Inc.; Novocure; Nuvalent; Nuvation Bio Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Revolution Medicines, Inc.; Roche; Summit Therapeutics, Inc.; and Takeda Pharmaceutical Company Limited

Dr. Hussein reports the following financial relationships:

Research Support: PI on one pharmaceutical study, Replimune RP1-104 IGNYTE.

Dr. Ricciuti reports the following financial relationships:

Advisory Board: AstraZeneca; Caris Life Sciences; Johnson & Johnson; and Lilly

Consultant: AstraZeneca; Caris Life Sciences; Johnson & Johnson; and Lilly

Research Support: AstraZeneca ESR (institutionally funded), start date 4/1/26

Dr. Sherry reports no financial relationships to disclose.

Dr. Yu reports the following financial relationships:

Advisory Board, Consultant, and Speakers Bureau: AbbVie Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb Company; Cullinan Therapeutics, Inc.; Daiichi Sankyo Company; Janssen Pharmaceuticals, Inc.; Pfizer, Inc.; Summit Therapeutics Inc.; and Taiho Oncology

Patient Planner:

Natalie Brown reports no financial relationships to disclose.

The following individuals have no financial relationships to disclose:
Alaa Bawaneh, MD, PhD (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Keshia Pitt, PhD (Planning Committee)
Taylor Wallace, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.